Abel Hall LLC
ALLO icon

Abel Hall LLC’s Allogene Therapeutics ALLO Stock Holding History

Abel Hall LLC’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$40K Sell
24,992
-1,356
-5% -$2.58K 0.01% 845
2026
Q2 		$54.8K Sell
26,348
-299
-1% -$657 0.01% 895
2026
Q1 		$65K Buy
26,647
+9,604
+56% +$19.2K 0.01% 723
2025
Q4 		$23.3K Buy
+17,043
New +$22.5K 0.01% 696

Other funds holding ALLO

Wildcat Capital Management
Wildcat Capital Management New York $174M AUM 46.5% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Harold Davidson & Associates
Harold Davidson & Associates Los Angeles, California $246M AUM 30.79% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
OpenArc Corporate Advisory
OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return
Indivisible Partners
Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Choreo LLC
Choreo LLC Rockford, Illinois $9.7B AUM 18.43% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Abel Hall LLC's ALLO Position: Q3 2026 in Review

Abel Hall LLC reduced its Allogene Therapeutics (ALLO) stake by 5.1% in Q3 2026, selling an estimated $2.58K and leaving 24,992 shares worth $40K. The position accounts for 0.01% of the portfolio, ranked #845.

Abel Hall LLC first reported a position in ALLO in Q4 2025 and has held it in 4 quarters since. The position peaked at $65K in Q1 2026. 40 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

  • Abel Hall LLC held 24,992 shares of Allogene Therapeutics worth $40K as of Q3 2026.
  • Abel Hall LLC sold 1,356 Allogene Therapeutics shares in Q3 2026, an estimated $2.58K.
  • Allogene Therapeutics made up 0.01% of Abel Hall LLC's portfolio in Q3 2026, its #845 holding.
  • Abel Hall LLC first reported a position in Allogene Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Abel Hall LLC's Allogene Therapeutics position peaked at $65K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.